All News Clarity Pharmaceuticals Ltd

Equities

CU6

AU0000165375

Market Closed - Australian S.E. Other stock markets 02:10:06 2024-05-08 am EDT			5-day change	1st Jan Change
3.92 ^AUD	+5.95%		+40.00%	+106.32%

Apr. 24	Clarity Pharmaceuticals Completes AU$10.8 Million Retail Entitlement Offer	MT
Apr. 04	Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clarity Pharmaceuticals Completes AU$10.8 Million Retail Entitlement Offer	Apr. 23	MT
Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes	Apr. 03	MT
Clarity Pharmaceuticals Concludes Placement and Institutional Entitlement Offer; Shares Decline 4%	Mar. 27	MT
Clarity Pharmaceuticals to Raise AU$121 Million via Fully Underwritten Equity Raising	Mar. 26	MT
Clarity Pharmaceuticals' SECuRE Trial Treats First Participant in Last Dose Escalation Cohort; Shares Down 5%	Mar. 21	MT
Clarity Pharmaceuticals Ltd(ASX:CU6) added to S&P/ASX All Ordinaries Index	Mar. 17	CI
Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial	Mar. 15	CI
Clarity Pharmaceuticals Prostate Cancer Trial Advances	Mar. 15	MT
Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range	Mar. 08	CI
Clarity Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Clarity Pharmaceuticals Reports Safety, Effectivity of Prostate Cancer Lesion Detection System in US Trial	Feb. 15	MT
Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors	Jan. 15	CI
Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA	Dec. 22	CI
Clarity Pharmaceuticals Doses First Patient in Phase Three Prostate Cancer Trial	Dec. 21	MT
Clarity Pharmaceuticals Closes Recruitment for Phase 2 Trial in Neuroendocrine Tumors	Dec. 19	MT
Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer	Nov. 30	CI
Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level	Nov. 30	CI
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort	Nov. 30	AQ
Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE	Nov. 29	CI
Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial	Nov. 07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Clarity Pharmaceuticals Ltd

Equities

CU6

AU0000165375

All News

Filters